“One Continuous Trial” In Oncology: US FDA Offers Guidance And Encouragement
One of the hallmarks of the “breakthrough” era has been the rapid expansion of first-in-human trials into pivotal studies for efficacy submissions. In a new draft guidance, FDA offers some initial thoughts on safeguards to make hyperfast development pathways successful.
You may also be interested in...
US FDA will continue expanded access activities as government shutdown continues, but CDER Director Woodcock says that platform trials can help eliminate the need for expanded access to exist.
Although guidance appears to be free of surprises, US FDA once again made a push for sponsors to adopt seamless trial designs.
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.